Alkaline Phosphatase and Duloxetine/Sertraline
Duloxetine can increase alkaline phosphatase levels, while sertraline does not typically affect this enzyme.
Duloxetine Effects on Alkaline Phosphatase
Duloxetine is associated with elevations in alkaline phosphatase as part of its hepatotoxicity profile. 1
- The FDA label explicitly states that "elevated transaminases, bilirubin, and alkaline phosphatase have occurred in patients" treated with duloxetine 1
- In placebo-controlled adult trials, duloxetine treatment was associated with small mean increases in alkaline phosphatase from baseline to endpoint 1
- A clinical study in elderly patients with major depressive disorder found a statistically significant increase in alkaline phosphatase with duloxetine compared to placebo (P = 0.017), though this was not considered clinically relevant 2
Hepatotoxicity Context
The alkaline phosphatase elevation occurs as part of duloxetine's broader hepatotoxic potential: 3
- Duloxetine has been associated with hepatic failure presenting as abdominal pain, hepatomegaly, and elevation of transaminase levels 3
- Cholestatic jaundice with minimal transaminase elevation has been reported, which would be expected to elevate alkaline phosphatase 3
- Duloxetine should be discontinued in patients who develop jaundice or other evidence of clinically significant liver dysfunction 3
Sertraline Effects on Alkaline Phosphatase
Sertraline does not have documented effects on alkaline phosphatase levels. 4
- The FDA label for sertraline does not list alkaline phosphatase elevations among its adverse effects or laboratory abnormalities 4
- Sertraline's hepatic effects are primarily related to its role as a CYP2D6 inhibitor affecting drug metabolism, not direct hepatotoxicity 4
Clinical Monitoring Recommendations
For duloxetine: 3
- Monitor for signs of liver dysfunction including jaundice, abdominal pain, and hepatomegaly
- Discontinue duloxetine immediately if jaundice or clinically significant liver dysfunction develops
- The American Academy of Child and Adolescent Psychiatry guidelines note that no specific laboratory tests are routinely recommended for SNRI monitoring, though this should be reconsidered if hepatic symptoms emerge 3
For sertraline: 4
- Routine alkaline phosphatase monitoring is not indicated based on the drug's safety profile